*Target Lesion Primary Patency (TLPP) of 71%, defined as the interval following the index intervention until the next clinically-driven reintervention at or adjacent to the original treatment site or until the extremity was abandoned for permanent access. Freedom from primary safety events = 96.4%, defined as freedom from any adverse events, localized or systemic, that reasonably suggests the involvement of the AV access circuit (not including stenosis or thrombosis) that require or result in any of the following alone or in combination: additional interventions (including surgery); in-patient hospitalization or prolongation of an existing hospitalization; or death. AVeVA Clinical Study. Data on File. Bard Peripheral Vascular Inc., Tempe AZ
Please consult Instructions for Use for product indications for use, contraindications, warnings, precautions, complications, adverse events and detailed safety information.